Other

Polarx Biopharmaceuticals, Inc.

Hospira, Inc.

Javelin Pharmaceuticals, Inc.

Innovative Drug Delivery Systems, Inc.

Fred H Mermelstein

Ralph M Ellison

Janet A Chollet

Curtis Wright

Daniel B Carr

Bernadette Klamerus

Randi Albin

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

Method of treating atrophic vaginitis

The present invention provides topical compositions and methods for administering tamoxifen citrate while minimizing the incidence and or severity of adverse drug experiences associated with tamoxifen therapy. In one aspect, these compositions and methods provide a lower plasma concentration of tamoxifen metabolites, such as 4-hydroxytamoxifen and N-desmethyltamoxifen, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient tamoxifen as the sole active agent to benefit a subject with tamoxifen therapy.

Compositions and methods for topical tamoxifen citrate therapy

The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 75 mg, e.g., from about 18.75 mg to about 37.5 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.

Formulations of low dose diclofenac and beta-cyclodextrin

The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

NMDA receptor antagonist formulation with reduced neurotoxicity

The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Growing community of inventors

Upper Montclair, NJ, United States of America

Fred H Mermelstein